Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Respiratory irritants in e-cigarette refill liquids across nine European countries: a threat to respiratory health?

Constantine Vardavas, Charis Girvalaki, Alexander Vardavas, Sophia Papadakis, Manolis Tzatzarakis, Panagiotis Behrakis, Aristidis Tsatsakis
European Respiratory Journal 2017 50: 1701698; DOI: 10.1183/13993003.01698-2017
Constantine Vardavas
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
2Institute of Public Health of the American College of Greece, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vardavas@tobcontrol.eu
Charis Girvalaki
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Vardavas
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia Papadakis
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
3Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manolis Tzatzarakis
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panagiotis Behrakis
2Institute of Public Health of the American College of Greece, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aristidis Tsatsakis
1Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Respiratory irritants within e-cigarette refill liquids are a cause for concern for respiratory health http://ow.ly/454g30gK09m

To the Editor:

The rapid expansion of the e-cigarette market across European countries has raised a number of concerns within the scientific community [1, 2]. The most recent data from across the European Union revealed a substantial increase in e-cigarette experimentation, with 15% of European citizens reporting having tried e-cigarettes in 2017, representing a 7.0% increase since 2012 [3]. Annual e-cigarette sales in Europe have reached EUR 1.33 billion, and are projected to reach over EUR 10 billion by 2020 [4].

It is important to note that despite the increasing popularity of e-cigarettes, there is new and emerging evidence documenting the potential health risks of using these products, particularly with regard to respiratory health. Previous research identified an increase in lung flow resistance after 5 min of e-cigarette product use and an associated decrease in fractional exhaled nitric oxide (FeNO) concentrations [5]. Several studies have indicated that the chemical substances and ultrafine particles of in e-cigarette vapour can cause dry cough and irritation of the pharynx and upper and lower respiratory system, and are also potentially toxic and carcinogenic [6, 7]. Furthermore, glycol and glycerol vapours and other mist components of e-cigarettes have been found to cause dryness of the mucous membranes and irritation of the upper airway [6]. Flavours used in e-cigarette liquids can also have an acute cytotoxic effect on respiratory cells, with menthol, coffee and strawberry flavours found to affect the overall cytotoxicity of the refill liquids [8]. Kosmider et al. [9] found that e-cigarette users are exposed to significant amounts of benzaldehyde, which is a known respiratory irritant, and those who use cherry-flavoured e-cigarette products may inhale significantly higher doses of benzaldehyde compared with users of other flavours. The latest revision to the European Tobacco Products Directive (TPD) has set out robust safety and quality standards for manufacturers and importers of e-cigarettes sold in the EU, in order to ensure a high level of health protection for European citizens [10]. The TPD mandates that, except for nicotine, ingredients used in the nicotine-containing liquid should not pose a risk to human health in heated or unheated form [10]. With this in mind, we aimed to identify and, where possible, quantify the existence of potential respiratory irritants within e-cigarette refill liquids, across nine European Union member states (EU MS).

Within the context of the Horizon 2020 EUREST-PLUS project, in 2016 we identified and purchased 122 randomly selected samples from the most popular e-cigarette brands in nine EU MS. The most popular brands were identified based on either sales data (Euromonitor) or on website visits if brand data were not available (www.alexa.com). Based on this methodology, a comprehensive list of all products available in the five most popular companies was generated and three products were then randomly selected from each company (n=122) for chemical analysis.

The analysis was performed by a previously validated gas chromatography–mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) method, and results were compared with the Globally Harmonised Classification System (GHS) classification for respiratory irritants [11, 12]. The e-liquid samples were analysed for their flavours and additive content. For the analysis of ethyl hexanoate, limonene, a-terpinolene, linalool, menthol, a-damascone, b-damascone, a-ionone and b-ionone, a GC-MS system equipped with an AOC-5000 robotic auto sampler using a SLBtm-5 ms (Supelco, Bellefonte, PA, USA) capillary column (30 m length, 0.25 mm internal diameter, 0.25 μm film thickness) was used. Methyl cyclopentenolone, ethyl maltol, 2,5-dimethylpyrazine, ethyl vanillin and 3,4-dimethoxybenzaldehyde compounds were determined and quantified by LC-MS.

In total, 246 different flavours and additives were detected among the samples tested, with the most common flavour substance detected being menthol (41.0%), followed by ethyl maltol (36.9%), linalool (31.1%), methyl cyclopentanolone (26.2%), beta-damascone (18.9%), ethyl vanillin (18.0%), b-ionone (10.7%), and acetyl pyrazine and a-ionone (9.0%) (table 1). The mean, minimum and maximum detected values (%, w/w) of the above were quantified (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Evaluation of potential respiratory irritants among popular e-cigarette refill liquids (n=122), across nine European Union member states in 2016

Moreover, all of the refill liquid samples analysed (122/122) were found to have additives that are classified to have some level of danger/risk of hazard based on the GHS classification. Specifically, both methyl cyclopentanolone and a-ionone may cause allergy or asthma symptoms or breathing difficulties if inhaled, while methyl cyclopentanolone is also able to cause respiratory irritations [13]. Other substances such as acetyl pyrazine, ethyl vanillin and menthol have also been found to cause respiratory irritation [13]. In addition to the role of the above substances as respiratory irritants based on the GHS classification, all have warnings about a wide range of effects, including skin, eye and respiratory irritation; allergies; harmful or even fatal effects if swallowed; induction of drowsiness or dizziness; suspected damage to fertility or the foetus; toxicity to aquatic life; and flammability [12].

Our study tested a randomly selected sample of e-cigarette liquids, based on available databases, immediately prior to the introduction of the TPD. Despite the large sample tested, we did not test all liquids available in Europe; it is possible that additional respiratory irritants may be contained in e-cigarette refills, and our results should be understood in the context of this limitation.

To our knowledge, this is the first attempt to identify the existence of respiratory irritants within e-cigarette refill liquids across EU MS, an area of potential concern for respiratory health. Our findings indicate potentially hazardous substances in e-cigarettes, contrary to Article 20 of the TPD, which clearly states that with the exception of nicotine, only ingredients that do not pose a risk to human health in heated or unheated form should be used in the liquid [10]. For this reason and in order to ensure the protection of European consumer's health, monitoring of e-cigarette additives is necessary and should be addressed urgently.

Footnotes

  • Support statement: This work was supported by a grant from the European Commission (Horizon2020 HCO-6-2015; EUREST-PLUS: 681109; Vardavas). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: None declared.

  • Received August 19, 2017.
  • Accepted September 19, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Filippidis FT,
    2. Laverty AA,
    3. Gerovasili V
    , et al. Two-year trends and predictors of e-cigarette use in 27 European Union member states. Tobacco Control 2017; 26: 98–104.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Zhu SH,
    2. Sun JY,
    3. Bonnevie E
    , et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control 2014; 23: Suppl. 3, iii3–iii9.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    European Commission. Special Eurobarometer 458: Attitudes of Europeans towards tobacco and electronic cigarettes. Brussels, European Union, 2017. Available from: http://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2146 Date last accessed: August 2017. Date last updated: May 2017.
  4. ↵
    Nasdaq Research and Markets. Europe $1.33 Billion E-cigarette and Vaporizer Device & Aftermarket Report 2017: Vape Shop Analysis and Forecasts 2016-2022. https://globenewswire.com/news-release/2017/02/24/927549/0/en/Europe-1-33-Billion-E-cigarette-and-Vaporizer-Device-Aftermarket-Report-2017-Vape-Shop-Analysis-and-Forecasts-2016-2022.html Date last accessed: August 2017. Date last updated: February 24, 2017.
  5. ↵
    1. Vardavas CI,
    2. Anagnostopoulos N,
    3. Kougias M
    , et al. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest 2012; 141: 1400–1406.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Callahan-Lyon P
    . Electronic cigarettes: human health effects. Tob Control 2014; 23: Suppl. 2, ii36–ii40.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Goniewicz ML,
    2. Knysak J,
    3. Gawron M
    . Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23: 133–139.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Leigh NJ,
    2. Lawton RI,
    3. Hershberger PA
    , et al. Flavourings significantly affect inhalation toxicity of aerosol generated from electronic nicotine delivery systems (ENDS). Tob Control 2016; 25: Suppl. 2, ii81–ii87.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kosmider L,
    2. Sobczak A,
    3. ProkopowiczA, Kurek J
    , et al. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. Thorax 2016; 71: 376–377.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products and repealing Directive 2001/37/EC. Available from: http://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A32014L0040 Date last accessed: August 2017. Date last updated: April 2014.
  11. ↵
    1. Kavvalakis PM,
    2. Stivaktakis DP,
    3. Tzatzarakis MN
    , et al. Multi-component analysis of replacement liquids of electronic cigarettes using chromatographic techniques. J Anal Toxicol 2015; 39: 262–269.
    OpenUrlCrossRefPubMed
  12. ↵
    1. United Nations Economic Commission for Europe
    . Globally Harmonized System of Classification and Labelling of Chemicals (GHS). New York, United Nations, 2007. Available from: http://www.unece.org/trans/danger/publi/ghs/ghs_rev02/02files_e.html Date last accessed: August 2017. Date last updated: 2011.
  13. ↵
    1. NCBI
    . PubChem Compound. https://pubchem.ncbi.nlm.nih.gov/compound Date last accessed: August 2017.
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 6 Table of Contents
European Respiratory Journal: 50 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Respiratory irritants in e-cigarette refill liquids across nine European countries: a threat to respiratory health?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Respiratory irritants in e-cigarette refill liquids across nine European countries: a threat to respiratory health?
Constantine Vardavas, Charis Girvalaki, Alexander Vardavas, Sophia Papadakis, Manolis Tzatzarakis, Panagiotis Behrakis, Aristidis Tsatsakis
European Respiratory Journal Dec 2017, 50 (6) 1701698; DOI: 10.1183/13993003.01698-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Respiratory irritants in e-cigarette refill liquids across nine European countries: a threat to respiratory health?
Constantine Vardavas, Charis Girvalaki, Alexander Vardavas, Sophia Papadakis, Manolis Tzatzarakis, Panagiotis Behrakis, Aristidis Tsatsakis
European Respiratory Journal Dec 2017, 50 (6) 1701698; DOI: 10.1183/13993003.01698-2017
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society